Physician profile
John M Huber
NPI 1649521758
$11,548.83
in general payments reported to CMS, 2019-2025
36 companies · $2,133 in 2025
The $2,133 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,185 · 2022: $1,941 · 2023: $2,514 · 2024: $2,776 · 2025: $2,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,417 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,416.62 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,608.45 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,822.95 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $971.69 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $935.35 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $661.74 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $399.50 | 2021-2025 | |
| Exact Sciences Corporation | $382.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $374.54 | 2022-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.76 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $299.96 | 2021-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $299.30 | 2021-2022 | |
| Amgen INC. | $296.86 | 2021-2024 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $294.68 | 2022-2025 | |
| Shield Therapeutics INC | $233.91 | 2023-2024 | Accrufer |
| Glaxosmithkline, LLC. | $227.87 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Huber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.